Research, Select, & Monitor Wednesday, April 08, 2020 4:56:33 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

Ticker Lookup
Mylan Inc$15.14$.775.36%

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  Mylan Inc vs Drugs - Generic

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

These companies have one thing in common; they manufacture, distribute, and sell generic drugs that are the chemical and therapeutic equivalent of a brand name drug for which the patent production has expired. One company of this group attempts to actually improve the generic drug through new methods of drug delivery and reformulation techniques, but that is not the norm.
 Totals Company Industry
  Sales: $11,500.5 Mil $11,648.9 Mil
  Market Cap: $7,416.8 Mil $8,319.5 Mil
  Analysts Recommendation: Buy Buy

 Averages Company Industry
  Historic Revenue: .6% .6%
  Estimated Revenue: 4.3% 39.8%
  Historic Earnings: (3.5%) (3.5%)
  Estimated Earnings: 1.2% 1.2%
  Stock Price (1 Year): (48.0%) (35.6%)
  Cash per Share: 22.4% 182.9%
  Dividend: N/A N/A
  Trailing PE: N/A N/A
  Forward PE: 3.2 3.2
  Price-to-Sales: .6 N/A
  Price-to-Book: .6 22.9
  Dividend Yield: N/A N/A
  Market Cap: $7,416.8 Mil $4,159.7 Mil
  Net Margin: .1% (32.7%)
  Gross Margin: 33.9% 66.9%
  Return on Equity: .0 (2.4)
  Return on Assets: .0 (.2)
  Balance Sheet
  Current Ratio: 1.2 2.2
  Quick Ratio: .7 2.0
  Cash Ratio: .1 1.6
  Debt-to-Equity: 1.6 5.7
  Interest Coverage: (.1) .2
  Relative-Strength Index: 37.9 N/A

 Other companies in Drugs - Generic Price Market Cap
  Esperion Therapeutics, Inc.  (ESPR) $33.03 $902.7 Mil

Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results, the logo, and News Selects are trademarks of
Copyright © 1998 - 2020 All rights reserved.